173 related articles for article (PubMed ID: 32721897)
1. Long-term outcome in multiple sclerosis patients treated with fingolimod.
Lattanzi S; Rocchi C; Danni M; Taffi R; Cerqua R; Carletti S; Silvestrini M
Mult Scler Relat Disord; 2020 Oct; 45():102416. PubMed ID: 32721897
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
[TBL] [Abstract][Full Text] [Related]
3. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
Boziki M; Bakirtzis C; Giantzi V; Sintila SA; Kallivoulos S; Afrantou T; Nikolaidis I; Ioannidis P; Karapanayiotides T; Koutroulou I; Parissis D; Grigoriadis N
Front Neurol; 2021; 12():699844. PubMed ID: 34497577
[No Abstract] [Full Text] [Related]
5. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen M; Mondot L; Bucciarelli F; Pignolet B; Laplaud DA; Wiertlewski S; Brochet B; Ruet A; Defer G; Derache N; Vermersch P; Zephir H; Debouverie M; Mathey G; Berger E; Cappé C; Labauge P; Carra C; De Seze J; Bigaut K; Brassat D; Lebrun-Frenay C
Mult Scler; 2021 Sep; 27(10):1556-1563. PubMed ID: 33124504
[TBL] [Abstract][Full Text] [Related]
6. Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
Cannizzaro M; Ferré L; Clarelli F; Giordano A; Sangalli F; Colombo B; Comi G; Moiola L; Martinelli V; Filippi M; Esposito F
J Neurol; 2022 Oct; 269(10):5596-5605. PubMed ID: 35759013
[TBL] [Abstract][Full Text] [Related]
7. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of reduced fingolimod dose in relapsing remitting multiple sclerosis-a Portuguese cohort.
Ramos-Lopes J; Batista S; Barradas P; Campelo I; Correia I; Nunes C; Macário C; Sousa L
Neurol Sci; 2021 Mar; 42(3):1039-1043. PubMed ID: 32719903
[TBL] [Abstract][Full Text] [Related]
9. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
[TBL] [Abstract][Full Text] [Related]
10. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S; Schmidt R; Straeten FA; Pul R; Kleinschnitz C; Wieshuber M; Lee DH; Linker RA; Doerck S; Straeten V; Windhagen S; Pawlitzki M; Aufenberg C; Lang M; Eienbroeker C; Tackenberg B; Limmroth V; Wildemann B; Haas J; Klotz L; Wiendl H; Ruck T; Meuth SG
J Neurol; 2019 Jan; 266(1):165-173. PubMed ID: 30446966
[TBL] [Abstract][Full Text] [Related]
12. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
Paolicelli D; Lucisano G; Manni A; Avolio C; Bonavita S; Brescia Morra V; Capobianco M; Cocco E; Conte A; De Luca G; De Robertis F; Gasperini C; Gatto M; Gazzola P; Lus G; Iaffaldano A; Iaffaldano P; Maimone D; Mallucci G; Maniscalco GT; Marfia GA; Patti F; Pesci I; Pozzilli C; Rovaris M; Salemi G; Salvetti M; Spitaleri D; Totaro R; Zaffaroni M; Comi G; Amato MP; Trojano M;
J Neurol; 2019 Dec; 266(12):3098-3107. PubMed ID: 31535270
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
[TBL] [Abstract][Full Text] [Related]
14. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.
Dominguez-Mozo MI; Galán V; Ramió-Torrentà L; Quiroga A; Quintana E; Villar LM; Costa-Frossard L; Fernández-Velasco JI; Villarrubia N; Garcia-Martinez MA; Arroyo R; Alvarez-Lafuente R
Front Immunol; 2024; 15():1384411. PubMed ID: 38911861
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
[TBL] [Abstract][Full Text] [Related]
16. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
[TBL] [Abstract][Full Text] [Related]
17. Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
Ferrè L; Mogavero A; Clarelli F; Moiola L; Sangalli F; Colombo B; Martinelli V; Comi G; Filippi M; Esposito F
Mult Scler; 2021 Aug; 27(9):1374-1383. PubMed ID: 32975468
[TBL] [Abstract][Full Text] [Related]
18. Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.
Zecca C; Roth S; Findling O; Perriard G; Bachmann V; Pless ML; Baumann A; Kamm CP; Lalive PH; Czaplinski A
Eur J Neurol; 2018 May; 25(5):762-767. PubMed ID: 29431876
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
[TBL] [Abstract][Full Text] [Related]
20. Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
Guger M; Enzinger C; Leutmezer F; Di Pauli F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2023 Jun; 270(6):3103-3111. PubMed ID: 36862148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
